Disease reactivation after fingolimod cessation in Multiple Sclerosis patients with pregnancy desire: A retrospective study.
Fingolimod-disease reactivation
Multiple Sclerosis
Pregnancy desire
Journal
Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
02
05
2022
revised:
13
07
2022
accepted:
21
07
2022
pubmed:
1
8
2022
medline:
20
10
2022
entrez:
31
7
2022
Statut:
ppublish
Résumé
Reactivation of Multiple Sclerosis (MS) activity has been described after fingolimod cessation. Because of its contra indication during pregnancy, switch towards lower efficacy treatments are frequent in MS patients with childbearing desire but expose them to a risk of disease reactivation. In this retrospective study including 44 women with MS, a significant increase of the median annualized relapse rate was found in the year following fingolimod discontinuation compared to the period before (p < 0.0001), and 57% of women experienced at least one relapse. When considering to start fingolimod, particular attention should be paid to women with a short-term pregnancy desire.
Identifiants
pubmed: 35908450
pii: S2211-0348(22)00574-0
doi: 10.1016/j.msard.2022.104066
pii:
doi:
Substances chimiques
Immunosuppressive Agents
0
Fingolimod Hydrochloride
G926EC510T
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
104066Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that there is no conflict of interest.